GlassScriptPhysician profile
Lukena Ulhas Karkhanis
NPI 1700198165
$376,780.99
in general payments reported to CMS, 2019-2025
49 companies · $90K in 2025
The $90K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,786 · 2020: $4,777 · 2021: $23K · 2022: $93K · 2023: $93K · 2024: $66K · 2025: $90K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $37K · Consulting Fee: $35K · Food and Beverage: $23K · Honoraria: $3,163 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $151,312.90 |
| Travel and Lodging | $37,326.95 |
| Consulting Fee | $34,853.80 |
| Food and Beverage | $22,640.20 |
| Honoraria | $3,163.00 |
| Education | $393.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $161,332.20 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $59,306.37 | 2020-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47,181.79 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Regeneron Healthcare Solutions, INC. | $41,682.85 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $14,897.57 | 2019-2025 | |
| Csl Behring | $8,570.02 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Incyte Corporation | $7,303.10 | 2022-2025 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $4,798.70 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Grifols USA, LLC | $4,558.20 | 2019-2025 | Xembify, Gamunex-C |
| Optinose US, INC. | $3,642.68 | 2019-2023 | |
| Genentech USA, INC. | $3,018.70 | 2019-2025 | Xolair |
| Blueprint Medicines Corporation | $2,648.41 | 2022-2025 | Ayvakit |
| Alk-Abello, INC | $2,077.55 | 2019-2025 | Odactra, Grastek, Ragwitek |
| Glaxosmithkline, LLC. | $1,985.23 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $1,747.08 | 2020-2025 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols Shared Services North America, INC. | $1,710.00 | 2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $1,382.38 | 2019-2025 | |
| Phadia US INC. | $1,318.48 | 2024 | Immunocap |
| Biocryst US Sales Co., LLC | $1,245.41 | 2021-2025 | Orladeyo |
| Galderma Laboratories, L.P. | $721.11 | 2025 | Nemluvio |
| Amgen INC. | $712.18 | 2021-2025 | Tezspire |
| Octapharma USA, INC. | $612.62 | 2021-2025 | Cutaquig, Panzyga, Octagam Immune Globulin (Human) |
| Ars Pharmaceuticals Operations, INC. | $437.44 | 2025 | Neffy |
| Pfizer INC. | $421.46 | 2019-2024 | |
| Pharming Healthcare, INC. | $399.39 | 2019-2025 | Ruconest |
| Kaleo, INC. | $381.28 | 2019-2023 | Auvi-Q |
| Mylan Specialty L.P. | $315.49 | 2019-2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $264.13 | 2019-2021 | |
| Adma Biomanufacturing LLC | $250.77 | 2020-2025 | |
| Aquestive Therapeutics, INC. | $222.59 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.69 | 2020-2022 | |
| Genentech, INC. | $174.56 | 2023-2025 | Xolair |
| Bio Products Laboratory USA, INC. | $139.84 | 2021-2023 | Gammaplex, Coagadex |
| Horizon Therapeutics Plc | $125.00 | 2021 | |
| Viatris Specialty LLC | $118.66 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $110.53 | 2024 | Xarelto |
| Lilly USA, LLC | $108.15 | 2024-2025 | Ebglyss, Taltz |
| Shire North American Group INC | $107.06 | 2019 | |
| Verona Pharma, INC. | $95.80 | 2025 | Ohtuvayre |
| Ionis Pharmaceuticals, INC. | $83.12 | 2025 | Dawnzera |
| Sunovion Pharmaceuticals INC. | $61.49 | 2019 | |
| Merck Sharp & Dohme LLC | $60.12 | 2021-2023 | |
| Organon LLC | $56.67 | 2025 | |
| Jubilant Hollisterstier LLC | $55.71 | 2019 | |
| Greer Laboratories, INC. | $47.79 | 2019-2025 | Palforzia |
| Gc Biopharma USA, INC. | $27.07 | 2025 | Alyglo |
| Circassia INC. | $18.15 | 2019 | |
| Cycle Pharmaceuticals INC | $17.25 | 2025 | Sajazir |
| Biocryst Pharmaceuticals, INC. | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lukena Karkhanis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.